Immunovant Beheer
Beheer criteriumcontroles 2/4
De CEO Immunovant is Pete Salzmann, benoemd in Dec2019, heeft een ambtstermijn van 4.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.55M, bestaande uit 8.2% salaris en 91.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.3% van de aandelen van het bedrijf, ter waarde $ 11.81M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.1 jaar en 4.9 jaar.
Belangrijke informatie
Pete Salzmann
Algemeen directeur
US$8.6m
Totale compensatie
| Percentage CEO-salaris | 8.2% |
| Dienstverband CEO | 4.9yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 3.1yrs |
| Gemiddelde ambtstermijn bestuur | 4.9yrs |
Recente managementupdates
Recent updates
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
Oct 16
Immunovant: Switching Lead Candidates Increases Risk
Oct 14We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Jul 18Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive
Jun 27We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Apr 19Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
Apr 04Immunovant: An Intriguing And Developing Story
Jan 25Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate
Jan 12We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Sep 28Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Jun 14Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
Mar 08We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Nov 06Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset
Oct 17Immunovant stock down on raising $75M though equity capital
Oct 04We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Aug 06Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Apr 06We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Jun 20Immunovant EPS beats by $0.04
Jun 01argenx rise even as Immunovant pauses the trial for anti-FcRn therapy
Feb 03Immunovant slips 7% on voluntary hold of IMVT-1401 dosing
Feb 02Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management
Jan 14Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?
Dec 30Immunovant (IMVT) Investor Presentation - Slideshow
Nov 16Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$323m |
| Jun 30 2024 | n/a | n/a | -US$273m |
| Mar 31 2024 | US$9m | US$700k | -US$259m |
| Dec 31 2023 | n/a | n/a | -US$243m |
| Sep 30 2023 | n/a | n/a | -US$255m |
| Jun 30 2023 | n/a | n/a | -US$245m |
| Mar 31 2023 | US$6m | US$625k | -US$211m |
| Dec 31 2022 | n/a | n/a | -US$199m |
| Sep 30 2022 | n/a | n/a | -US$177m |
| Jun 30 2022 | n/a | n/a | -US$167m |
| Mar 31 2022 | US$6m | US$600k | -US$157m |
| Dec 31 2021 | n/a | n/a | -US$138m |
| Sep 30 2021 | n/a | n/a | -US$128m |
| Jun 30 2021 | n/a | n/a | -US$111m |
| Mar 31 2021 | US$15m | US$567k | -US$107m |
| Dec 31 2020 | n/a | n/a | -US$100m |
| Sep 30 2020 | n/a | n/a | -US$79m |
| Jun 30 2020 | n/a | n/a | -US$73m |
| Mar 31 2020 | US$9m | US$361k | -US$66m |
Compensatie versus markt: De totale vergoeding ($USD 8.55M ) Pete } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.56M ).
Compensatie versus inkomsten: De vergoeding van Pete is gestegen terwijl het bedrijf verliesgevend is.
CEO
Pete Salzmann (56 yo)
4.9yrs
Tenure
US$8,552,430
Compensatie
Dr. Peter Salzmann, also known as Pete, M.D., M.B.A. is the Chief Executive Officer and Director of Immunovant, Inc. since December 2019. Dr. Salzmann has served as a member of Immunovant Sciences Ltd.’s b...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairperson of the Board | 4.9yrs | US$3.69m | 0.014% $ 537.6k | |
| CEO & Director | 4.9yrs | US$8.55m | 0.30% $ 11.8m | |
| Chief Technology Officer | 1.6yrs | US$4.04m | geen gegevens | |
| Chief Financial Officer | 3.1yrs | US$2.07m | 0.091% $ 3.6m | |
| Chief Operating Officer | no data | geen gegevens | geen gegevens | |
| Chief Legal Officer & Corporate Secretary | 2.8yrs | geen gegevens | 0.076% $ 3.0m | |
| Vice President of Marketing | 4.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Human Resources | no data | geen gegevens | geen gegevens | |
| Chief Medical Officer | 3.4yrs | US$1.92m | 0.13% $ 5.3m | |
| Senior Vice President of Strategic Finance | no data | geen gegevens | geen gegevens | |
| Chief Medical Officer | less than a year | geen gegevens | 0.016% $ 638.2k | |
| Senior Vice President of Program & Alliance Management | no data | geen gegevens | geen gegevens |
3.1yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van IMVT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairperson of the Board | 4.9yrs | US$3.69m | 0.014% $ 537.6k | |
| CEO & Director | 4.9yrs | US$8.55m | 0.30% $ 11.8m | |
| Independent Director | 4.9yrs | US$291.32k | 0.027% $ 1.0m | |
| Director | 5.1yrs | US$445.00k | 0.012% $ 479.6k | |
| Independent Director | 5.1yrs | US$287.62k | 0.022% $ 869.3k | |
| Independent Director | 4.9yrs | US$436.30k | 0.012% $ 490.3k | |
| Director | 4.8yrs | US$55.00k | geen gegevens |
4.9yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van IMVT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).